FeesSafety
Pluang+

UBS reaffirms buy on 3i Group as Action's sales recovery boosts outlook

Market News
17 Sep 2026
Proactive Investors
View Source
Bullish
UBS reaffirms buy on 3i Group as Action's sales recovery boosts outlook

UBS has maintained its 'buy' rating on 3i Group PLC, highlighting improving sales at Action, its key holding that represents over 70% of its portfolio. Evidence from anonymized card spending data shows continued sales growth in France and Germany, signaling a recovery after a previous slump. UBS forecasts 4.2% like-for-like sales growth and 11% earnings growth for Action this year, with 3i's half-year results in November expected to provide further proof of recovery. The shares could rise if confidence returns, narrowing the valuation gap between market price and book value.

3i Group's recent vote of confidence is presented here with Pluang's market data for context. For readers following Financials, here is Pluang's market snapshot as of Sep 17, 2026 23:31 WIB: of 74 priced Financials-sector US stocks tradable on Pluang, 57 rose and 16 fell today. Notable movers include TCPC at USD 4.04 (+4.94%), SAN at USD 14.81 (+2.85%), and NDAQ at USD 91.27 (+2.83%).

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
50 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
50 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Joseph Lubin, co-founder of Ethereum, predicts that artificial intelligence (AI) and cryptocurrency will merge on the Ethereum blockchain to create a system where automated tasks are commissioned, completed, and paid for with trust guaranteed by bloc...

Protocol Fundamentals
Bullish
4 hours ago
Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin's price dropped to around $80,494, down 1.26%, alongside a 14.11% decline in trading volume, indicating weaker market participation. Despite increased network activity and a slight rise in Bitcoin's market dominance, sentiment remained neutra...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App